No connection

Search Results

AUNA vs EBS

AUNA
Auna SA
NEUTRAL
Price
$5.66
Market Cap
$418.9M
Sector
Healthcare
AI Confidence
65%
EBS
Emergent BioSolutions Inc.
BEARISH
Price
$8.03
Market Cap
$414.7M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AUNA
5.78
EBS
8.63
Forward P/E
AUNA
5.64
EBS
2.69
P/B Ratio
AUNA
0.87
EBS
0.8
P/S Ratio
AUNA
0.1
EBS
0.56
EV/EBITDA
AUNA
4.78
EBS
3.8

Profitability

Gross Margin
AUNA
38.68%
EBS
49.44%
Operating Margin
AUNA
14.83%
EBS
-15.2%
Profit Margin
AUNA
4.34%
EBS
7.08%
ROE
AUNA
11.41%
EBS
10.46%
ROA
AUNA
5.81%
EBS
5.33%

Growth

Revenue Growth
AUNA
-0.9%
EBS
-23.6%
Earnings Growth
AUNA
-50.9%
EBS
--

Financial Health

Debt/Equity
AUNA
2.06
EBS
1.12
Current Ratio
AUNA
0.9
EBS
5.01
Quick Ratio
AUNA
0.7
EBS
2.19

Dividends

Dividend Yield
AUNA
--
EBS
--
Payout Ratio
AUNA
0.0%
EBS
0.0%

AI Verdict

AUNA NEUTRAL

AUNA exhibits a Piotroski F-Score of 6/9, indicating stable financial health, but lacks an Altman Z-Score, limiting distress risk assessment. The stock appears undervalued with a current price of $5.66 versus a Graham Number of $12.0, suggesting defensive fair value, though growth metrics are weak with negative earnings and revenue growth. Profitability margins and ROE are positive, but high debt/equity and declining earnings raise concerns. Analysts recommend a 'buy' with a target price of $8.77, implying upside potential, but recent price volatility and deteriorating fundamentals temper bullishness.

Strengths
Piotroski F-Score of 6/9 indicates stable financial health
Attractive valuation with P/E of 5.78 well below sector average of 209.16
Price/Book of 0.87 suggests shares trade below book value
Risks
Debt/Equity ratio of 2.06 is high, increasing financial risk
Current ratio of 0.90 and quick ratio of 0.70 indicate potential liquidity issues
Earnings growth (YoY) down -50.90%, signaling severe profitability deterioration
EBS BEARISH

EBS presents as a classic value trap, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between its Graham Number ($14.48) and Intrinsic Value ($6.51). While the stock appears cheap on a P/E and P/S basis, this is offset by a severe revenue contraction of -23.6% YoY and negative operating margins (-15.20%). The combination of bearish insider sentiment, a 0/100 technical trend, and extreme earnings volatility suggests that the current price is not yet reflecting the full extent of the fundamental decay.

Strengths
Strong short-term liquidity with a Current Ratio of 5.01
Low valuation multiples (P/E 8.63, P/S 0.56)
Healthy Gross Margin of 49.44%
Risks
Significant revenue decline (-23.6% YoY and -24.04% Q/Q)
Negative operating margins indicating an unsustainable core business model
Bearish insider activity with consistent selling and zero buying

Compare Another Pair

AUNA vs EBS: Head-to-Head Comparison

This page compares Auna SA (AUNA) and Emergent BioSolutions Inc. (EBS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile